In a landmark decision, the US Food and Drug Administration (FDA) has extended its approval of Jemperli (dostarlimab) to include all adult patients with primary advanced or recurrent endometrial cancer. This expanded approval now encompasses patients with mismatch repair proficient (MMRp) or microsatellite stable (MSS) tumours, which account for the majority of endometrial cancer cases. […]
In a significant development for patients with primary advanced or recurrent endometrial cancer, GSK plc (LSE/NYSE: GSK) has disclosed promising outcomes for Jemperli (dostarlimab-gxly) from the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial. The trial’s Part 1 and Part 2 findings, which showcase notable improvements in overall survival (OS) and progression-free survival (PFS), respectively, were unveiled in a […]
Biopharma company GSK has secured the full approval of the US Food and Drug Administration (FDA) for its Jemperli (dostarlimab-gxly) drug for recurrent or advanced mismatch repair-deficient endometrial cancer. Jemperli is indicated for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has advanced or after a prior platinum-containing […]